New challenges in endpoints for drug development in advanced melanoma.

@article{Ribas2012NewCI,
  title={New challenges in endpoints for drug development in advanced melanoma.},
  author={Antoni Ribas and Peter Hersey and Mark R. Middleton and Helen J. Gogas and Keith T. Flaherty and Vernon K. Sondak and John Munn Kirkwood},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2012},
  volume={18 2},
  pages={336-41}
}
During the past 3 decades, the field of clinical research for the treatment of advanced melanoma lacked significant advances. Available drugs had low antitumor activity and no proven benefit in overall survival. Recently, new drugs developed based on an in-depth understanding of the biology of this disease have shown significant benefit, with ipilimumab and vemurafenib having recently shown a positive impact in overall survival in patients with metastatic melanoma leading to approval in this… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

BRIM-2: An Open-label, multicenter Phase II study of RG7204 (PLX4032) in previously treated patients with BRAF V600E Endpoints in Melanoma www.aacrjournals.org Clin Cancer Res

  • A Ribas, K Kim, L Schuchter, R Gonzalez, AC Pavlick, J Weber
  • January 15,
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…